image
Healthcare - Drug Manufacturers - General - NASDAQ - US
$ 104.33
-0.201 %
$ 130 B
Market Cap
22.63
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GILD stock under the worst case scenario is HIDDEN Compared to the current market price of 104 USD, Gilead Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GILD stock under the base case scenario is HIDDEN Compared to the current market price of 104 USD, Gilead Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GILD stock under the best case scenario is HIDDEN Compared to the current market price of 104 USD, Gilead Sciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GILD

image
$120.0$120.0$115.0$115.0$110.0$110.0$105.0$105.0$100.0$100.0$95.0$95.0$90.0$90.0$85.0$85.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
28.8 B REVENUE
6.04%
1.66 B OPERATING INCOME
-78.15%
480 M NET INCOME
-91.45%
10.8 B OPERATING CASH FLOW
35.25%
-3.45 B INVESTING CASH FLOW
-52.27%
-3.43 B FINANCING CASH FLOW
33.01%
7.57 B REVENUE
0.32%
2.45 B OPERATING INCOME
176.01%
1.78 B NET INCOME
0.00%
2.98 B OPERATING CASH FLOW
-30.96%
-225 M INVESTING CASH FLOW
68.31%
2.26 B FINANCING CASH FLOW
263.89%
Balance Sheet Gilead Sciences, Inc.
image
Current Assets 19.2 B
Cash & Short-Term Investments 11.6 B
Receivables 4.42 B
Other Current Assets 3.18 B
Non-Current Assets 39.8 B
Long-Term Investments 0
PP&E 5.41 B
Other Non-Current Assets 34.4 B
19.61 %7.49 %5.40 %9.18 %58.32 %Total Assets$59.0b
Current Liabilities 12 B
Accounts Payable 833 M
Short-Term Debt 1.82 B
Other Current Liabilities 9.36 B
Non-Current Liabilities 27.7 B
Long-Term Debt 1.3 B
Other Non-Current Liabilities 26.4 B
4.57 %23.54 %3.26 %66.54 %Total Liabilities$39.7b
EFFICIENCY
Earnings Waterfall Gilead Sciences, Inc.
image
Revenue 28.8 B
Cost Of Revenue 6.25 B
Gross Profit 22.5 B
Operating Expenses 20.8 B
Operating Income 1.66 B
Other Expenses 1.18 B
Net Income 480 M
30b30b25b25b20b20b15b15b10b10b5b5b0029b(6b)23b(21b)2b(1b)480mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
78.26% GROSS MARGIN
78.26%
5.78% OPERATING MARGIN
5.78%
1.67% NET MARGIN
1.67%
2.48% ROE
2.48%
0.81% ROA
0.81%
2.36% ROIC
2.36%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Gilead Sciences, Inc.
image
20b20b18b18b16b16b14b14b12b12b10b10b8b8b6b6b4b4b2b2b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 480 M
Depreciation & Amortization 2.77 B
Capital Expenditures -523 M
Stock-Based Compensation 835 M
Change in Working Capital -880 M
Others 6.75 B
Free Cash Flow 10.3 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Gilead Sciences, Inc.
image
Wall Street analysts predict an average 1-year price target for GILD of $92 , with forecasts ranging from a low of $71 to a high of $132 .
GILD Lowest Price Target Wall Street Target
71 USD -31.95%
GILD Average Price Target Wall Street Target
92 USD -11.82%
GILD Highest Price Target Wall Street Target
132 USD 26.52%
Price
Max Price Target
Min Price Target
Average Price Target
1401401301301201201101101001009090808070706060Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.84% DIVIDEND YIELD
0.79 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
3.503.503.003.002.502.502.002.001.501.501.001.000.500.500.000.000.430.520.570.630.680.710.730.750.770.790.430.470.520.570.630.680.710.730.750.770.430.470.520.570.630.680.710.730.750.770.431.720.471.930.522.130.572.340.632.570.682.750.712.860.732.940.753.020.773.100.002015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Gilead Sciences, Inc.
image
Sold
0-3 MONTHS
30.8 M USD 1
3-6 MONTHS
42.6 M USD 4
6-9 MONTHS
5.57 M USD 2
9-12 MONTHS
137 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an aggressive type of breast cancer. reuters.com - 1 week ago
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS ≥ 10). The. businesswire.com - 1 week ago
Here's Why Gilead Sciences (GILD) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2 weeks ago
What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings Evaluate the expected performance of Gilead (GILD) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 2 weeks ago
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings? Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now. zacks.com - 2 weeks ago
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions. zacks.com - 2 weeks ago
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com - 2 weeks ago
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one. businesswire.com - 3 weeks ago
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the preceding trading day. zacks.com - 3 weeks ago
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report? Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com - 3 weeks ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. zacks.com - 3 weeks ago
8. Profile Summary

Gilead Sciences, Inc. GILD

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 130 B
Dividend Yield 0.84%
Description Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Contact 333 Lakeside Drive, Foster City, CA, 94404 https://www.gilead.com
IPO Date Jan. 22, 1992
Employees 17600
Officers Mr. Daniel P. O'Day Chairman & Chief Executive Officer Mr. Andrew D. Dickinson Chief Financial Officer Ms. Deborah H. Telman J.D. Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary Ms. Johanna Mercier Chief Commercial Officer Ms. Diane E. Wilfong Interim Corporate Controller, Chief Accounting Officer & Principal Accounting Officer Ms. Jacquie Ross C.F.A. Vice President of Investor Relations Ms. Jyoti K. Mehra Executive Vice President of Human Resources Dr. Linda Slanec Higgins Ph.D. Senior Vice President of Research, Innovation & Portfolio Dr. Flavius Martin M.D. Executive Vice President of Research Dr. Rudolf Ertl Senior Vice President of Commercial Operations of Australia, Canada, Europe